Invest in

Drug-Patent Cliffs

6.6%
4.7%
0.0%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
6.6%
4.7%
0.0%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for as low as $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
Open a Motif account to view and trade this basket of stocks:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 1.6%
26.7% Dr. Reddy's Laboratories Ltd RDY 1.0%
22.0% Taro Pharmaceutical Industries Ltd. TARO 4.4%
19.1% Abbott Laboratories ABT 34.3%
8.1% 8xx 8xxxxxxxx 8xxxxxx 8xxx 88.8%
5.0% 8xxxx 8xxx 8xx 88.8%
4.5% 8xxx 8xxxxxxxxxxxxx 8xxxxxxxxx 8xxxxxx 8 8xxx 88.8%
3.9% 8xxx 8xxxxxxxxxxxx 8xx 8xxx 88.8%
2.9% 8xxxxxx 8xxxxxxxxxxxxxx 8xxx 8xxx 88.8%
2.4% 8xxxxxx 8x 8xx 8xx 88.8%
2.2% 8xxxx 8xxx 8xxx 88.8%
1.3% 8xxxxxxxxxxx 8xx 8xx 88.8%
1.1% 8xxxxxxx 8xxx 8xxx 88.8%
0.8% 8xxxxxx 8xxxxxxxxxx 8xx 88.8%

Quotes delayed 15 mins. Currently Dec 17, 2018 4:46:35 AM. Fields are marked with -- when data is unavailable.